The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Open accessAbstract
BACKGROUND: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic effects, and the manufacture of the cells is complex. Natural killer (NK) cells that have been modified to express an anti-CD19 CAR have the potential to overcome these limitations. METHODS: CAR-NK cells per kilogram of body weight) after lymphodepleting chemotherapy. RESULTS: The administration of CAR-NK cells was not associated with the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease, and there was no increase in the levels of inflammatory cytokines, including interleukin-6, over baseline. The maximum tolerated dose was not reached. Of the 11 patients who were treated, 8 (73%) had a response; of these patients, 7 (4 with lymphoma and 3 with CLL) had a complete remission, and 1 had remission of the Richter's transformation component but had persistent CLL. Responses were rapid and seen within 30 days after infusion at all dose levels. The infused CAR-NK cells expanded and persisted at low levels for at least 12 months. CONCLUSIONS: Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects. (Funded by the M.D. Anderson Cancer Center CLL and Lymphoma Moonshot and the National Institutes of Health; ClinicalTrials.gov number, NCT03056339.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The trial in adults with chronic lymphocytic leukemia demonstrated that CAR-NK targeting CD19 are safe and effective [143].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [143]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, the results from studies on targets other than CD19 in CAR-NK have been less than satisfactory, including both in vivo studies and clinical research.”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [143]
Experimental — accuracy not yet measuredIn the citing paper
“In a recent study of NK-cell CAR therapy, there were no reported cases of cytokine storm or even elevated interleukin-6 levels,60”
From Cytokine storm (2020) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationTisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Self-citationChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Miller, J. S., Soignier, Y., Panoskaltsis‐Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D. H., Le, C. T., DeFor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,894
Cited by
Sorted by citations
Items 401–500 of 1,000
Nonviral genome engineering of natural killer cells
Robbins, G. M., Wang, M., Pomeroy, E. J., & Moriarity, B. S. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02406-6 · Cited by 57
Self-citationHeterodimeric IL-15 in Cancer Immunotherapy
Bergamaschi, C., Stravokefalou, V., Stellas, D., Karaliota, S., Felber, B. K., & Pavlakis, G. N. (2021) · Cancers · doi:10.3390/cancers13040837 · Cited by 53
Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future
Sanchez‐Petitto, G., Rezvani, K., Daher, M., Rafei, H., Kebriaei, P., Shpall, E. J., & Olson, A. L. (2023) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szac086 · Cited by 52
Self-citationAzeez, S. S., Yashooa, R. K., Smail, S., Salihi, A., Ali, A. S., Mamand, S., & Janson, C. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02386-8 · Cited by 56
Reighard, S. D., Cranert, S. A., Rangel, K., Ali, A., Gyurova, I. E., de la Cruz-Lynch, A. T., Tuazon, J. A., Khodoun, M. V., Kottyan, L. C., Smith, D. F., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100003 · Cited by 53
Deciphering Natural Killer Cell Homeostasis
Pfefferle, A., Jacobs, B., Haroun-Izquierdo, A., Kveberg, L., Sohlberg, E., & Malmberg, K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00812 · Cited by 57
High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management
Jain, P., Dreyling, M. H., Seymour, J. F., & Wang, M. L. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02287 · Cited by 53
Self-citationThe depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells
Laba, S., Mallett, G., & Amarnath, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.022 · Cited by 54
2024 Update: Advances in the risk stratification and management of large B‐cell lymphoma
Tavakkoli, M., & Barta, S. K. (2023) · American Journal of Hematology · doi:10.1002/ajh.27075 · Cited by 54
Integration of ζ-deficient CARs into the CD3 ζ gene conveys potent cytotoxicity in T and NK cells
Kath, J., Franke, C., Drosdek, V., Du, W., Glaser, V., Fuster‐García, C., Stein, M., Zittel, T., Schulenberg, S., Porter, C. E., et al. (2024) · Blood · doi:10.1182/blood.2023020973 · Cited by 52
The extracellular matrix in solid tumor immunotherapy
Cho, Y., & Doh, J. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.07.009 · Cited by 52
Progress and challenges in developing allogeneic cell therapies
Deuse, T., & Schrepfer, S. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.03.004 · Cited by 51
NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development
Dezfouli, A. B., Yazdi, M., Pockley, A. G., Khosravi, M., Kobold, S., Wagner, E., & Multhoff, G. (2021) · Cells · doi:10.3390/cells10123390 · Cited by 53
Natural Killer Cell-Mediated Immunotherapy for Leukemia
Allison, M., Mathews, J., Gilliland, T. M., & Mathew, S. O. (2022) · Cancers · doi:10.3390/cancers14030843 · Cited by 50
Ruppel, K. E., Fricke, S., Koehl, U., & Schmiedel, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.822298 · Cited by 53
Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer
Kennedy, P. R., Felices, M., & Miller, J. S. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02769-4 · Cited by 50
The Advances and Challenges of NK Cell-Based Cancer Immunotherapy
Kang, S., Gao, X., Zhang, L., Yang, E., Li, Y., & Yu, L. (2021) · Current Oncology · doi:10.3390/curroncol28020105 · Cited by 50
Investigational drugs for the treatment of diffuse large B-cell lymphoma
Patriarca, A., & Gaïdano, G. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1855140 · Cited by 48
Feeder Cells at the Interface of Natural Killer Cell Activation, Expansion and Gene Editing
Gurney, M., Kundu, S., Pandey, S., & O'Dwyer, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.802906 · Cited by 42
Soldierer, M., Bister, A., Haist, C., Thivakaran, A., Cengiz, S. C., Sendker, S., Bartels, N., Thomitzek, A., Smorra, D., Hejazi, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.847008 · Cited by 49
Plasticity of NK cells in Cancer
Corvino, D., Kumar, A., & Bald, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.888313 · Cited by 51
Cichocki, F. M., Zhang, B., Wu, C.-Y., Chiu, E., Day, A., O’Connor, R. S., Yackoubov, D., Simantov, R., McKenna, D. H., Cao, Q., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade3341 · Cited by 49
Nano/genetically engineered cells for immunotherapy
Shen, J., Zhou, Y., & Yin, L. (2024) · BMEMat · doi:10.1002/bmm2.12112 · Cited by 50
Adoptive Cell Therapy in Breast Cancer: A Current Perspective of Next-Generation Medicine
Fuentes‐Antrás, J., Guevara‐Hoyer, K., Baliu‐Piqué, M., García-Sáenz, J. Á., Pérez‐Segura, P., Pandiella, A., & Ocaña, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.605633 · Cited by 49
Pekar, L., Klausz, K., Busch, M., Valldorf, B., Kolmar, H., Wesch, D., Oberg, H., Krohn, S., Boje, A. S., Gehlert, C. L., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2001004 · Cited by 49
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Sanmamed, M. F., Berraondo, P., Rodriguez-Ruiz, M. E., & Melero, I. (2022) · Nature Cancer · doi:10.1038/s43018-022-00401-1 · Cited by 50
Guo, X., Mahlakõiv, T., Ye, Q., Somanchi, S. S., He, S., Rana, H., DiFiglia, A., Gleason, J., van der Touw, W., HARIRI, R. J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001975 · Cited by 48
Molecular Basis and Role of Siglec-7 Ligand Expression on Chronic Lymphocytic Leukemia B Cells
Chang, L., Liang, S., Lu, S., Tseng, H.-C., Tsai, H.-Y., Tang, C.-J., Sugata, M., Chen, Y., Chen, Y., Wu, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.840388 · Cited by 47
Chaudhry, K., Geiger, A. E., Dowlati, E. P., Lang, H., Sohai, D. K., Hwang, E. I., Lazarski, C. A., Yvon, E. S., Holdhoff, M., Jones, R., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.10.010 · Cited by 49
Wang, L., Wang, Y., He, X., Mo, Z., Zhao, M., Liang, X., Hu, K., Wang, K., Yue, Y., Mo, G., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101889 · Cited by 48
CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit
Yi, F., Cohen, T., Zimmerman, N., Dündar, F., Zumbo, P., Eltilib, R., Brophy, E. J., Arkin, H., Feucht, J., Gormally, M. V., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01009-x · Cited by 55
Oncolytic viruses: advanced strategies in cancer therapy
Xiao, D., Zhang, H., Liu, Y., Li, Y., Li, G., & Ning, Y. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02343-3 · Cited by 58
Immune Checkpoint Inhibitors — The Need for Innovation
Johnson, P. C., Gainor, J. F., Sullivan, R. J., Longo, D. L., & Chabner, B. A. (2023) · New England Journal of Medicine · doi:10.1056/nejmsb2300232 · Cited by 48
Janelle, V., & Delisle, J. (2021) · Cancers · doi:10.3390/cancers13040598 · Cited by 52
Immunotherapy for the treatment of multiple myeloma
Boussi, L. S., Avigan, Z. M., & Rosenblatt, J. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1027385 · Cited by 48
Regenerative medicine applications: An overview of clinical trials
Petrosyan, A., Martins, P. N. A., Solez, K., Uygun, B. E., Gorantla, V. S., & Orlando, G. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.942750 · Cited by 48
Natural Killer Cell-Based Immunotherapy against Glioblastoma
Morimoto, T., Nakazawa, T., Maeoka, R., Nakagawa, I., Tsujimura, T., & Matsuda, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032111 · Cited by 51
Merdan, S., Subramanian, K., Ayer, T., Weyenbergh, J. V., Chang, A., Koff, J. L., & Flowers, C. R. (2021) · Blood Cancer Journal · doi:10.1038/s41408-020-00404-0 · Cited by 46
Wendel, P., Reindl, L. M., Bexte, T., Künnemeyer, L., Särchen, V., Albinger, N., Mackensen, A., Rettinger, E., Bopp, T., & Ullrich, E. (2021) · Cancers · doi:10.3390/cancers13061481 · Cited by 48
Outsmarting trogocytosis to boost CAR NK/T cell therapy
Ramezani, F. M., Meymandi, A. R. P., Akbari, B., Tamtaji, O. R., Mirzaei, H., Brown, C. E., & Mirzaei, H. R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01894-9 · Cited by 47
CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy
Guo, S., Lei, W., Jin, X., Liu, H., Wang, J. Q., Deng, W., & Qian, W. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012202 · Cited by 46
Immunotherapy with NK cells: recent developments in gene modification open up new avenues
Reindl, L. M., Albinger, N., Bexte, T., Müller, S. C., Hartmann, J., & Ullrich, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777651 · Cited by 48
Wang, M., Krueger, J. B., Gilkey, A. K., Stelljes, E. M., Kluesner, M. G., Pomeroy, E. J., Skeate, J. G., Slipek, N. J., Lahr, W. S., Claudio Vázquez, P. N., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009560 · Cited by 45
Self-citationTherapeutic strategies for gastric cancer targeting immune cells: Future directions
Zhao, Y. F., Bai, Y., Shen, M., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992762 · Cited by 46
The role of interleukin-15 in the development and treatment of hematological malignancies
Sindaco, P., Pandey, H., Isabelle, C., Chakravarti, N., Brammer, J. E., Porcu, P., & Mishra, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1141208 · Cited by 45
The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells
Kaulfuß, M., Mietz, J., Fabri, A., Berg, J. V., Münz, C., & Chijioke, O. (2023) · Scientific Reports · doi:10.1038/s41598-023-37779-6 · Cited by 50
Precision off-the-shelf natural killer cell therapies for oncology with logic-gated gene circuits
Frankel, N. W., Deng, H., Yucel, G., Gainer, M., Leemans, N., Lam, A., Li, Y., Hung, M. E., Lee, D., Lee, C.-T., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114145 · Cited by 49
Umbilical cord blood: The promise and the uncertainty
Kindwall‐Keller, T. L., & Ballen, K. K. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0288 · Cited by 45
Devillier, R., Chrétien, A.-S., Pagliardini, T., Salem, N., Blaise, D., & Olive, D. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0920-198rr · Cited by 49
Thangaraj, J. L., Ahn, S., Jung, S., Vo, M.-C., Chu, T.-H., Phan, M. T., Kwon, M., Lee, K., Kim, M., Song, G., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00686-9 · Cited by 44
CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy
Elmas, E., Saljoughian, N., Pereira, M. D. S. F., Tullius, B. P., Sorathia, K., Nakkula, R. J., Lee, D. A., & Kararoudi, M. N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.834002 · Cited by 47
How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy
Biederstädt, A., & Rezvani, K. (2022) · Blood · doi:10.1182/blood.2021012411 · Cited by 45
Self-citationNext Generation Natural Killer Cells for Cancer Immunotherapy
Rossi, F., Fredericks, N., Snowden, A., Allegrezza, M. J., & Moreno‐Nieves, U. Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.886429 · Cited by 47
Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing
Bai, R., & Cui, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.890166 · Cited by 46
Keshavarz, A., Salehi, A., Khosravi, S., Shariati, Y., Nasrabadi, N., Kahrizi, M. S., Maghsoodi, S., Mardi, A., Azizi, R., Jamali, S., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03163-w · Cited by 47
Mansour, A. G., Teng, K., Li, Z., Zhu, Z. G., Chen, H., Tian, L., Ali, A., Zhang, J., Lu, T., Ma, S., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022007405 · Cited by 44
Donald, A. M., Guipouy, D., Lemieux, W., Harvey, M., Bordeleau, L., Guay, D. R. P., Roméro, H., Li, Y., Dion, R., Béland, K., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1231916 · Cited by 44
Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy
Singh, N., & Maus, M. V. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.010 · Cited by 44
CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation
Eitler, J., Rackwitz, W., Wotschel, N., Gudipati, V., Shankar, N. M., Sidorenkova, A., Huppa, J. B., Ortíz-Montero, P., Opitz, C., Künzel, S. R., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008155 · Cited by 44
Kurebayashi, Y., Choyke, P. L., & Sato, N. (2020) · Nanotheranostics · doi:10.7150/ntno.51391 · Cited by 45
Adoptive cell therapy: Living drugs against cancer
Laskowski, T. J., & Rezvani, K. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20200377 · Cited by 44
Self-citationReagan, P. M., & Neelapu, S. S. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01616 · Cited by 44
Self-citationImmune System Investigation Using Parasitic Helminths
Douglas, B. B., Oyesola, O. O., Cooper, M. M., Posey, A. D., Wojno, E. D. T., Giacomin, P., & Herbert, D. R. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-093019-122827 · Cited by 44
Targeting NK Cells to Enhance Melanoma Response to Immunotherapies
Lee, H., da Silva, I. P., Palendira, U., Scolyer, R. A., Long, G. V., & Wilmott, J. S. (2021) · Cancers · doi:10.3390/cancers13061363 · Cited by 45
Reusing, S. B., Vallera, D. A., Manser, A. R., Watrin, T., Bhatia, S., Felices, M., Miller, J. S., Uhrberg, M., & Babor, F. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03008-0 · Cited by 44
Identifying SARS‐CoV‐2 ‘memory’ NK cells from COVID‐19 convalescent donors for adoptive cell therapy
Herrera, L., Martin‐Inaraja, M., Santos, S. J., Inglés‐Ferrándiz, M., Azkarate, A., Pérez-Vaquero, M. Á., Vesga, M. Á., Vicario, J. L., Soria, B., Solano, C., et al. (2021) · Immunology · doi:10.1111/imm.13432 · Cited by 44
Guan, P., Guo, Z., Xu, S., Hai-feng, L., Wang, L., Gu, Z., & Liu, Z. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202301202 · Cited by 43
Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies
Kikushige, Y. (2020) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.20036 · Cited by 48
Li, H.-K., Hsiao, C.-W., Yang, S.-H., Yang, H., Wu, T., Lee, C.-Y., Lin, Y., Pan, J., Cheng, Z.-F., Lai, Y.-D., et al. (2021) · Cancers · doi:10.3390/cancers13112724 · Cited by 44
The preclinical and clinical progress of cell sheet engineering in regenerative medicine
Hu, D., Li, X., Li, J., Tong, P., Li, Z., Lin, G., Sun, Y. J., & Wang, J. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03340-5 · Cited by 43
New cell sources for CAR-based immunotherapy
Mazinani, M., & Rahbarizadeh, F. (2023) · Biomarker Research · doi:10.1186/s40364-023-00482-9 · Cited by 43
Senescence, NK cells, and cancer: navigating the crossroads of aging and disease
Gergues, M., Bari, R., Koppisetti, S., Gosiewska, A., Kang, L., & HARIRI, R. J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1565278 · Cited by 46
Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges
Jasinski, S., Reyes, F. A. D. L., Yametti, G. C., Pierro, J., Raetz, E. A., & Carroll, W. L. (2020) · Pediatric Drugs · doi:10.1007/s40272-020-00413-3 · Cited by 42
Grote, S., Ureña-Bailén, G., Chan, K. C.-H., Baden, C., Mezger, M., Handgretinger, R., & Schleicher, S. (2021) · Cells · doi:10.3390/cells10051020 · Cited by 41
Engineering stem cells for cancer immunotherapy
Li, Y.-R., Zhou, Y., Kramer, A. B., & Yang, L. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.08.004 · Cited by 42
The promise and perils of immunotherapy
Lesch, S., & Gill, S. I. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004453c · Cited by 44
Colomar-Carando, N., Gauthier, L., Merli, P., Loiacono, F., Canevali, P., Falco, M., Galaverna, F., Rossi, B., Bosco, F., Caratini, M., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0843 · Cited by 42
Development of Stem Cell-Derived Immune Cells for Off-the-Shelf Cancer Immunotherapies
Li, Y.-R., Dunn, Z. S., Zhou, Y., Lee, D. P. H., & Yang, L. (2021) · Cells · doi:10.3390/cells10123497 · Cited by 42
Seliger, B., & Koehl, U. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.910595 · Cited by 42
Gurney, M., O’Reilly, E., Corcoran, S., Brophy, S., Krawczyk, J., Otto, N., Hermanson, D., Childs, R. W., Szegezdi, É., & O'Dwyer, M. E. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.07.008 · Cited by 40
Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer
Raftery, M. J., Franzén, A. S., Radecke, C., Boulifa, A., Schönrich, G., Stintzing, S., Blohmer, J., & Pecher, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109038 · Cited by 41
Control of nutrient uptake by IRF4 orchestrates innate immune memory
Santosa, E. K., Kim, H., Rückert, T., Luduec, J.-B. L., Abbasi, A. J., Wingert, C. K., Peters, L., Frost, J. N., Hsu, K. C., Romagnani, C., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01620-z · Cited by 40
The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance
Kilian, M., Friedrich, M., Lu, K. H.-N., Vonhören, D., Jansky, S., Michel, J., Keib, A., Stange, S., Hackert, N. S., Kehl, N., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adj7970 · Cited by 43
Genetically engineered hypoimmunogenic cell therapy
Hotta, A., Schrepfer, S., & Nagy, A. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00219-9 · Cited by 44
CAR-NK Cell Therapy: A Transformative Approach to Overcoming Oncological Challenges
Li, W., Wang, X., Zhang, X., Aziz, A. U. R., & Wang, D. (2024) · Biomolecules · doi:10.3390/biom14081035 · Cited by 45
Zhan, L., Zhang, J., Zhang, J., Liu, X., Zhu, S., Shi, Y., He, Y., Wang, W., Fan, Y., Tang, Z., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.12.031 · Cited by 40
CAR-NK Cells: A Chimeric Hope or a Promising Therapy?
Sabbah, M., Jondreville, L., Lacan, C., Norol, F., Vieillard, V., Roos‐Weil, D., & Nguyen, S. (2022) · Cancers · doi:10.3390/cancers14153839 · Cited by 42
Natural killer cells in cancer immunotherapy
Wang, D., Dou, L., Sui, L., Xue, Y., & Xu, S. (2024) · MedComm · doi:10.1002/mco2.626 · Cited by 47
Emerging combined CAR-NK cell therapies in cancer treatment: Finding a dancing partner
Hosseinalizadeh, H., Wang, L.-S., Mirzaei, H., Amoozgar, Z., Tian, L., & Yu, J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.057 · Cited by 44
Morcillo-Martín-Romo, P., Valverde-Pozo, J., Ortiz-Bueno, M., Arnone, M., Espinar‐Barranco, L., Espinar-Barranco, C., & García-Rubiño, M. E. (2025) · Biomedicines · doi:10.3390/biomedicines13040857 · Cited by 40
CARs: Beyond T Cells and T Cell-Derived Signaling Domains
Sievers, N. M., Dörrie, J., & Schaft, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103525 · Cited by 40
Kim, H. T., Shaughnessy, C. J., Rai, S. C., Reynolds, C. G., Ho, V. T., Cutler, C. S., Koreth, J., Gooptu, M., Romee, R., Nikiforow, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002184 · Cited by 40
Navin, I., Lam, M. T., & Parihar, R. (2020) · Cancers · doi:10.3390/cancers12123871 · Cited by 40
Schubert, M., Rohrbach, R., Schmitt, M. W., & Stein‐Thoeringer, C. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670286 · Cited by 40
Ringquist, R., Ghoshal, D., Jain, R., & Roy, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114003 · Cited by 39
CAR-NK Cells from Engineered Pluripotent Stem Cells: Off-the-shelf Therapeutics for all Patients
Lu, S., & Feng, Q. (2021) · Stem Cells Translational Medicine · doi:10.1002/sctm.21-0135 · Cited by 41
Dynamic variability in SHP-1 abundance determines natural killer cell responsiveness
Wu, Z., Park, S., Lau, C. M., 田中, 義., Sheppard, S., Sun, J. C.-Y., Das, J., Altan-Bonnet, G. Y., & Hsu, K. C. (2021) · Science Signaling · doi:10.1126/scisignal.abe5380 · Cited by 40
Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancer
Li, Y., Rezvani, K., & Rafei, H. (2023) · Immunological Reviews · doi:10.1111/imr.13255 · Cited by 41
Self-citationColorectal Cancer Immunotherapy: State of the Art and Future Directions
Cornista, A. M., Giolito, M. V., Baker, K., Hazime, H., Dufait, I., Datta, J., Khumukcham, S. S., De Ridder, M., Roper, J., Abreu, M. T., et al. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.007 · Cited by 39
Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors
Quamine, A. E., Olsen, M. R., Cho, M. M., & Capitini, C. M. (2021) · Cancers · doi:10.3390/cancers13112796 · Cited by 39
Metadata
- Authors
- Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., Nandivada, V., Kaur, I., Nunez Cortes, A., Cao, K., Daher, M., Hosing, C., Cohen, E. N., Kebriaei, P., Mehta, R., Neelapu, S., Nieto, Y., Wang, M., Wierda, W., Keating, M., Champlin, R., Shpall, E. J., & Rezvani, K.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- From the Departments of Stem Cell Transplantation and Cellular Therapy (E.L., D.M., P.B., R.B., L.N.K., B.O., M. Kaplan, V.N., I.K., A.N.C., M.D., C.H., P.K., R.M., Y.N., R.C., E.J.S., K.R.), Nuclear Medicine (H.A.M.), Leukemia (P. Thompson, W.W., M. Keating), Biostatistics (P. Thall), Laboratory Medicine (K.C.), Hematopathology (E.N.C.), and Lymphoma and Myeloma (S.N., M.W.), University of Texas M.D. Anderson Cancer Center, Houston.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-06
- Volume
- 382
- Issue
- 6
- Pages
- 545-553
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7101242
- OpenAlex
- W3004611567
- Cited by
- 2,217
- References
- 37
- Citations by year
- 2026: 282 · 2025: 337 · 2024: 332 · 2023: 323 · 2022: 353 · 2021: 379 · 2020: 205
- FWCI
- 113.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- M.D. Anderson Cancer Center CLL and lymphoma Moonshot Grants
- National Institutes of Health (1 R01 CA211044-01, 5P01CA148600-03, CA016672, P50CA100632-16)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CAR-NK cells, chimeric antigen receptor, natural killer cells, anti-CD19, relapsed or refractory B-cell lymphoma, chronic lymphocytic leukemia, Richter transformation, lymphodepleting chemotherapy, cytokine release syndrome, neurotoxicity, graft-versus-host disease, interleukin-6, CAR T-cell toxicity
- MeSH terms
- Receptors, Chimeric Antigen, Aged, Female, Fetal Blood, Genetic Vectors, Humans, Killer Cells, Natural, Lymphoma, Non-Hodgkin, Male, Middle Aged, Remission Induction, Retroviridae, Leukemia, Lymphocytic, Chronic, B-Cell, Antigens, CD19, Transplantation Conditioning, Allografts, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
